Accuray’s (ARAY)
consistently inconsistent performance means that I can’t honestly say
I’m surprised that its fiscal third-quarter results were disappointing,
but it does continue a very frustrating trend. Accuray continues to
struggle to attain and maintain any momentum in the slow-growing
radiation oncology market, despite solid clinical data and some
attractive system performance characteristics. While the earnings-driven
sell-off does take the share price back below my estimates of fair
value, these shares really aren’t going to work unless and until the
company can show that it can achieve operating profitability and
something more than just low single-digit revenue growth.
Continue here:
Accuray Moves Back From A Spark To A Damp Squib
No comments:
Post a Comment